2005PubMedRequires access

[Prevalence for seropositivity for HIV, hepatitis B and hepatitis C in blood donors].

María Rebeca F. Rivera-López, Celia Zavala-Méndez, Alfonso Arenas-Esqueda

Open publisher page 24 citations

Abstract

Despite utilizing different actions to render blood safe for transfusions, we continue to have the risk of transmitting some viral infections. For this reason, it is important to determine prevalence of infections due to HIV and hepatitis B and hepatitis C viruses in blood donors. Previous studies from Mexico indicate that HIV prevalence is 0.01 to 0.13%, while it is 0.11 to 1.22% for hepatitis B, and for hepatitis C, prevalence is 0.47 to 1.47%. We are checking the results of the screening tests (ELISA 3rd generation and chemiluminescent immunoassays) from blood donors studied at the Central Blood Bank (Banco Central de Sangre) at the Mexican Institute of Social Security's (IMSS) Twentieth First Century National Medical Center in Mexico City from 1995 to 2002. Reactive results were studied by confirmatory tests, Western Blot for HIV, AgHBs neutralization test for hepatitis B, and RIBA-HCV3.0 for hepatitis C. Reactive results from 513,062 blood donors confirmed for HV were 0.07%, reactive results and confirmation of hepatitis B from 511,733 blood donors were 0.13%, and reactive results and confirmation of hepatitis C from 511,115 blood donors were 0.31%. Rates obtained are low when compared with results of previous studies in Mexico for HIV, hepatitis B, and hepatitis C. It may be possible than these low rates indicate the positive impact obtained from preventive actions, better strategies of detection of blood donors with high risk, and the advantage of working with a fully automated test system with state-of-the-art technology.

About this research paper

What this paper is about

Despite utilizing different actions to render blood safe for transfusions, we continue to have the risk of transmitting some viral infections. For this reason, it is important to determine prevalence of infections due to HIV and hepatitis B and hepatitis C viruses in blood donors. Previous studies from Mexico indicate that HIV prevalence is 0.01 to 0.13%, while it is 0.11 to 1.22% for hepatitis B, and for hepatitis C, prevalence is 0.47 to 1.47%. We are checking the results of the screening tests (ELISA 3rd generation and chemiluminescent immunoassays) from blood donors studied at the Central Blood Bank (Banco Central de Sangre) at the Mexican Institute of Social Security's (IMSS) Twentieth First Century National Medical Center in Mexico City from 1995 to 2002. Reactive results were studied by confirmatory tests, Western Blot for HIV, AgHBs neutralization test for hepatitis B, and RIBA-HCV3.0 for hepatitis C. Reactive results from 513,062 blood donors confirmed for HV were 0.07%, reactive results and confirmation of hepatitis B from 511,733 blood donors were 0.13%, and reactive results and confirmation of hepatitis C from 511,115 blood donors were 0.31%. Rates obtained are low when compared with results of previous studies in Mexico for HIV, hepatitis B, and hepatitis C. It may be possible than these low rates indicate the positive impact obtained from preventive actions, better strategies of detection of blood donors with high risk, and the advantage of working with a fully automated test system with state-of-the-art technology.

Why it matters

OpenAlex reports 24 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Despite utilizing different actions to render blood safe for transfusions, we continue to have the risk of transmitting some viral infections. For this reason, it is important to determine prevalence of infections due to HIV and hepatitis B and hepatitis C viruses in blood donors. Previous studies from Mexico indicate that HIV prevalence is 0.01 to 0.13%, while it is 0.11 to 1.22% for hepatitis B, and for hepatitis C, prevalence is 0.47 to 1.47%. We are checking the results of the screening tests (ELISA 3rd generation and chemiluminescent immunoassays) from blood donors studied at the Central Blood Bank (Banco Central de Sangre) at the Mexican Institute of Social Security's (IMSS) Twentieth First Century National Medical Center in Mexico City from 1995 to 2002. Reactive results were studied by confirmatory tests, Western Blot for HIV, AgHBs neutralization test for hepatitis B, and RIBA-HCV3.0 for hepatitis C. Reactive results from 513,062 blood donors confirmed for HV were 0.07%, reactive results and confirmation of hepatitis B from 511,733 blood donors were 0.13%, and reactive results and confirmation of hepatitis C from 511,115 blood donors were 0.31%. Rates obtained are low when compared with results of previous studies in Mexico for HIV, hepatitis B, and hepatitis C. It may be possible than these low rates indicate the positive impact obtained from preventive actions, better strategies of detection of blood donors with high risk, and the advantage of working with a fully automated test system with state-of-the-art technology.

Key concepts: Medicine, Hepatitis C, Hepatitis B, Hepatitis, Viral hepatitis, Virology, Human immunodeficiency virus (HIV), Immunology

Related papers

Back to paper searchBrowse research topicsOriginal source
[Prevalence for seropositivity for HIV, hepatitis B and hepatitis C in blood donors]. — Research Paper | ScholarLens